The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients

Author:

Aghamohammadzadeh Nasser1,Niafar Mitra1,Dalir Abdolahinia Elham2,Najafipour Farzad1,Mohamadzadeh Gharebaghi Saeed3,Adabi Khadijeh4,Dalir Abdolahinia Elaheh5,Ahadi Hamidreza1

Affiliation:

1. Department of Endocrinology, Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

2. Endocrine Research Center, Tabriz University of Medical Sciences, Golgasht Avenue, Tabriz, Iran

3. Cardiology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

4. Department of Gynecology and Obstetrics, Tehran University of Medical Sciences, Tehran, Iran

5. Department of Biotechnology, Zanjan University of Medical Sciences, Zanjan, Iran

Abstract

Background: Pioglitazone is one of the antidiabetic agents used in the management of type 2 diabetes mellitus (DM). The effect of pioglitazone on blood glucose, lipid profile, liver enzymes and weight has been shown with conflicting results. In this study we aim to evaluate the effect of pioglitazone on the weight, lipid profile and liver enzymes in patients with DM. Methods: In this single-arm clinical trial, 110 poorly controlled diabetic type 2 patients (63.6% female with mean age of 54.26 ± 8.96 years) who were on maximal dosage of metformin and glibenclamide were enrolled. Patients were treated with pioglitazone for 3 months and laboratory. Fasting blood sugar (FBS), haemoglobin A1C (HbA1C), cholesterol, triglyceride, low-density lipoprotein (LDL) and high-density lipoprotein (HDL), alkaline phosphatase (ALK-P), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and weight changes were measured before and at the end of the study. Results: The levels of FBS ( p < 0.001), HbA1c ( p < 0.001), triglyceride ( p = 0.001), ALT ( p = 0.005) and ALK-P ( p = 0.001) were significantly decreased, but weight was significantly increased ( p < 0.001) after the intervention. There were no significant difference in cholesterol, LDL and HDL values before and after study. Conclusion: Although pioglitazone causes a significant decrease in FBS, HbA1C and triglyceride levels, it is associated with weight gain, which would limit its utility. IRCT registration code: IRCT201209276712N2

Publisher

SAGE Publications

Subject

Endocrinology, Diabetes and Metabolism

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3